News
Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
StockStory.org on MSN23h
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Firms like Moderna that are rapidly adopting AI and will have a higher mix of AI software robots to humans in the future ...
Moderna 57, a new Italian restaurant next to the Syosset train station, offers over 100 dishes to diners. The owner, Paul ...
Enphase Energy (ENPH) retained its spot as the most shorted S&P 500 (SP500) stock as a percentage of float in June, followed ...
Explore more
This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...
StockStory.org on MSN2d
Why Moderna (MRNA) Stock Is Falling TodayWhat Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...
Sioux City put a damper on Cleburne’s series-winning streak as the Railroaders dropped all three games to the Explorers over ...
The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results